Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              The Impact of Disease Severity on Responder Rates in a Phase 2b Study of XEN1101, a Potent, Selective Potassium Channel Opener, in Adults with Focal Epilepsy (X-TOLE)

              Author:Porter, Roger   French, Jacqueline   Perucca, Emilio   Brodie, Martin   Harden, Cynthia   Luzon Rosenblut, Constanza   Qian, Jenny   Kenney, Christopher   Beatch, Gregory   

              Session Name:S19: Epilepsy Clinical Trials and Long-term Studies  

              Topic:Epilepsy/Clinical Neurophysiology (EEG)  

              Program Number:S19.004  

              Author Institution:University of Pennsylvania, Philadelphia, PA  New York University Grossman School of Medicine and NYU Langone Health, New York, NY  Monash University, Melbourne, VI, Australia, and University of Melbourne (Austin Health), Heidelberg, Australia  University of Glasgow Department of Medicine and Therapeutics, Western Infirmary, Glasgow, Scotland, United Kingdom  Xenon Pharmaceuticals Inc., Vancouver, BC, Canada  

              Interim Long-term Safety and Efficacy of XEN1101, a Potent, Selective Potassium Channel Opener: Update from an Ongoing Open-label Extension of a Phase 2b Study (X-TOLE) in Adults with Focal Epilepsy

              Author:French, Jacqueline   Porter, Roger   Perucca, Emilio   Brodie, Martin   Rogawski, Michael   Harden, Cynthia   Qian, Jenny   Luzon Rosenblut, Constanza   Kenney, Christopher   Beatch, Gregory   

              Session Name:S19: Epilepsy Clinical Trials and Long-term Studies  

              Topic:Epilepsy/Clinical Neurophysiology (EEG)  

              Program Number:S19.005  

              Author Institution:New York University Grossman School of Medicine and NYU Langone Health, New York, NY  University of Pennsylvania, Philadelphia, PA  Monash University, Melbourne, VI, Australia, and University of Melbourne (Austin Health), Heidelberg, Australia  University of Glasgow Department of Medicine and Therapeutics, Western Infirmary, Glasgow, Scotland, United Kingdom  School of Medicine, University of California, Davis, Sacramento, CA  Xenon Pharmaceuticals Inc., Vancouver, BC, Canada